{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:44:53Z","timestamp":1791881093107,"version":"4.3.4"},"reference-count":134,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This review aims to highlight anti-proliferative, pro-apoptotic, and androgen\nreceptor-degrading activity of selected steroid and terpenoid derivatives in cancer cells,\nprimarily in prostate cancer cells. Steroid and terpenoid derivatives (steroid hybrids,\ncomprising androstane or pregnane skeleton associated with nitrogen containing heterocycle,\nsome natural sterols, bile acids, and related semi-synthetic derivatives; oleanane\nand ursane type pentacyclic triterpenoids; lanostane and dammarane type tetracyclic\ntriterpenoids), were reported earlier to cause the death of cancer cells via apoptosis;\nsome compounds exhibited significant anticancer potency in vivo and may be considered\nas promising anticancer agents. The presented data indicate that direct interaction\nof steroid and terpenoid derivatives with the key oncogenic protein MDM2 makes a\nsignificant contribution to anti-proliferative, pro-apoptotic, and androgen receptordegrading\nactivity of these compounds. It triggers apoptosis, which leads to cell death.\nStructural optimization of steroid and terpenoid derivatives can significantly increase\ntheir affinity to MDM2 and improve their anti-proliferative, pro-apoptotic, and androgen\nreceptor-degrading activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673373971250625075309","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:38:53Z","timestamp":1754455133000},"page":"2770-2793","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Participation of MDM2 in Pro-Apoptotic and Androgen Receptor- Degrading Potency of Selected Steroid and Terpenoid Derivatives"],"prefix":"10.2174","volume":"33","author":[{"given":"Alexander Y.","family":"Misharin","sequence":"first","affiliation":[{"name":"V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Veselovsky","sequence":"additional","affiliation":[{"name":"V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Zolottsev","sequence":"additional","affiliation":[{"name":"V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia"},{"name":"RUDN University, 6 Miklukho-Maklaya Street, 117198, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/jm501239f","volume":"58","author":"Njar V.C.O.","year":"2015","unstructured":"Njar V.C.O.; Brodie A.M.H.; Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer. J Med Chem  2015,58(5),2077-2087","journal-title":"J Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S1128","DOI":"10.21037\/tcr.2017.08.29","volume":"6","author":"Njar V.C.O.","year":"2017","unstructured":"Njar V.C.O.; Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy. Transl Cancer Res  2017,6(S7),S1128-S1131","journal-title":"Transl Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.2174\/0929867328666210208113919","volume":"28","author":"Latysheva A.S.","year":"2021","unstructured":"Latysheva A.S.; Zolottsev V.A.; Pokrovsky V.S.; Khan I.I.; Misharin A.Y.; Novel nitrogen containing steroid derivatives for prostate cancer treatment. Curr Med Chem  2021,28(40),8416-8432","journal-title":"Curr Med Chem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"116882","DOI":"10.1016\/j.bmc.2022.116882","volume":"69","author":"Huo H.","year":"2022","unstructured":"Huo H.; Li G.; Shi B.; Li J.; Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids. Bioorg Med Chem  2022,69,116882","journal-title":"Bioorg Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"108852","DOI":"10.1016\/j.steroids.2021.108852","volume":"171","author":"Hou Y.","year":"2021","unstructured":"Hou Y.; Shang C.; Meng T.; Lou W.; Anticancer potential of cardiac glycosides and steroid-azole hybrids. Steroids  2021,171,108852","journal-title":"Steroids"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/138920112798868719","volume":"13","author":"Patlolla J.M.R.","year":"2012","unstructured":"Patlolla J.M.R.; Rao C.V.; Triterpenoids for cancer prevention and treatment: Current status and future prospects. Curr Pharm Biotechnol  2012,13(1),147-155","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2174\/1389557521666210810153627","volume":"22","author":"Gupta N.","year":"2022","unstructured":"Gupta N.; A review on recent developments in the anticancer potential of oleanolic acid and its analogs (2017-2020). Mini Rev Med Chem  2022,22(4),600-616","journal-title":"Mini Rev Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/17460441.2021.1956901","volume":"16","author":"Hussain H.","year":"2021","unstructured":"Hussain H.; Ali I.; Wang D.; Hakkim F.L.; Westermann B.; Ahmed I.; Ashour A.M.; Khan A.; Hussain A.; Green I.R.; Shah S.T.A.; Glycyrrhetinic acid: A promising scaffold for the discovery of anticancer agents. Expert Opin Drug Discov  2021,16(12),1497-1516","journal-title":"Expert Opin Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.3390\/ijms22073676","volume":"22","author":"Lombrea A.","year":"2021","unstructured":"Lombrea A.; Scurtu A.D.; Avram S.; Pavel I.Z.; Turks M.; Lugi\u0146ina J.; Peipi\u0146\u0161 U.; Dehelean C.A.; Soica C.; Danciu C.; Anticancer potential of betulonic acid derivatives. Int J Mol Sci  2021,22(7),3676","journal-title":"Int J Mol Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2174\/1389203724666230418123409","volume":"24","author":"Banerjee J.","year":"2023","unstructured":"Banerjee J.; Samanta S.; Ahmed R.; Dash S.K.; Bioactive pentacyclic triterpenes trigger multiple signalling pathways for selective apoptosis leading to anticancer efficacy: Recent updates and future perspectives. Curr Protein Pept Sci  2023,24(10),820-842","journal-title":"Curr Protein Pept Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.3390\/molecules27196552","volume":"27","author":"Nistor G.","year":"2022","unstructured":"Nistor G.; Trandafirescu C.; Prodea A.; Milan A.; Cristea A.; Ghiulai R.; Racoviceanu R.; Mioc A.; Mioc M.; Ivan V.; \u0218oica C.; Semisynthetic derivatives of pentacyclic triterpenes bearing heterocyclic moieties with therapeutic potential. Molecules  2022,27(19),6552","journal-title":"Molecules"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3390\/molecules26092401","volume":"26","author":"Khwaza V.","year":"2021","unstructured":"Khwaza V.; Mlala S.; Oyedeji O.O.; Aderibigbe B.A.; Pentacyclic triterpenoids with nitrogen-containing heterocyclic moiety, privileged hybrids in anticancer drug discovery. Molecules  2021,26(9),2401","journal-title":"Molecules"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2174\/1871520611009050424","volume":"10","author":"Ferreira I.C.F.R.","year":"2010","unstructured":"Ferreira I.C.F.R.; Vaz J.A.; Vasconcelos M.H.; Martins A.; Compounds from wild mushrooms with antitumor potential. Anticancer Agents Med Chem  2010,10(5),424-436","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejmech.2019.04.039","volume":"174","author":"Liang C.","year":"2019","unstructured":"Liang C.; Tian D.; Liu Y.; Li H.; Zhu J.; Li M.; Xin M.; Xia J.; Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y. Eur J Med Chem  2019,174,130-141","journal-title":"Eur J Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.17795\/jjnpp-7171","volume":"7","author":"Ameri A.","year":"2012","unstructured":"Ameri A.; Ganoderic Acid in the treatment of prostate cancer. Jundishapur J Nat Pharm Prod  2012,7(3),85-86","journal-title":"Jundishapur J Nat Pharm Prod"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00280-006-0300-z","volume":"59","author":"Wang W.","year":"2007","unstructured":"Wang W.; Zhao Y.; Rayburn E.R.; Hill D.L.; Wang H.; Zhang R.; In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol  2007,59(5),589-601","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fphar.2012.00025","volume":"3","author":"Nag S.A.","year":"2012","unstructured":"Nag S.A.; Qin J-J.; Wang W.; Wang M-H.; Wang H.; Zhang R.; Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol  2012,3,25","journal-title":"Front Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1039\/C4NP00080C","volume":"32","author":"Wong A.S.T.","year":"2015","unstructured":"Wong A.S.T.; Che C.M.; Leung K.W.; Recent advances in ginseng as cancer therapeutics: A functional and mechanistic overview. Nat Prod Rep  2015,32(2),256-272","journal-title":"Nat Prod Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biopha.2018.01.155","volume":"100","author":"Majeed F.","year":"2018","unstructured":"Majeed F.; Malik F.Z.; Ahmed Z.; Afreen A.; Afzal M.N.; Khalid N.; Ginseng phytochemicals as therapeutics in oncology: Recent perspectives. Biomed Pharmacother  2018,100,52-63","journal-title":"Biomed Pharmacother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"738914","DOI":"10.3389\/fphar.2021.738914","volume":"12","author":"Tan M.M.","year":"2021","unstructured":"Tan M.M.; Chen M.H.; Han F.; Wang J.W.; Tu Y.X.; Role of bioactive constituents of Panax notoginseng in the modulation of tumorigenesis: A potential review for the treatment of cancer. Front Pharmacol  2021,12,738914","journal-title":"Front Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"113756","DOI":"10.1016\/j.biopha.2022.113756","volume":"156","author":"Yao W.","year":"2022","unstructured":"Yao W.; Guan Y.; Ginsenosides in cancer: A focus on the regulation of cell metabolism. Biomed Pharmacother  2022,156,113756","journal-title":"Biomed Pharmacother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"117049","DOI":"10.1016\/j.biopha.2024.117049","volume":"177","author":"Yang Y.","year":"2024","unstructured":"Yang Y.; Nan Y.; Du Y.; Liu W.; Ning N.; Chen G.; Gu Q.; Yuan L.; Ginsenosides in cancer: Proliferation, metastasis, and drug resistance. Biomed Pharmacother  2024,177,117049","journal-title":"Biomed Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(03)01001-7","volume":"89","author":"Vargas D.A.","year":"2003","unstructured":"Vargas D.A.; Takahashi S.; Ronai Z.; Mdm2: A regulator of cell growth and death. Adv Cancer Res  2003,89,1-34","journal-title":"Adv Cancer Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/cas.14433","volume":"111","author":"Dobbelstein M.","year":"2020","unstructured":"Dobbelstein M.; Levine A.J.; Mdm2: Open questions. Cancer Sci  2020,111(7),2203-2211","journal-title":"Cancer Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.3390\/ijms23095005","volume":"23","author":"Koo N.","year":"2022","unstructured":"Koo N.; Sharma A.K.; Narayan S.; Therapeutics targeting p53-MDM2 interaction to induce cancer cell death. Int J Mol Sci  2022,23(9),5005","journal-title":"Int J Mol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.2174\/187152009789124628","volume":"9","author":"Rayburn E.","year":"2009","unstructured":"Rayburn E.; Ezell S.; Zhang R.; Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem  2009,9(8),882-903","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.gendis.2018.07.002","volume":"5","author":"Qin J.J.","year":"2018","unstructured":"Qin J.J.; Li X.; Hunt C.; Wang W.; Wang H.; Zhang R.; Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis  2018,5(3),204-219","journal-title":"Genes Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","volume":"76","author":"Wang W.","year":"2024","unstructured":"Wang W.; Albadari N.; Du Y.; Fowler J.F.; Sang H.T.; Xian W.; McKeon F.; Li W.; Zhou J.; Zhang R.; MDM2 inhibitors for cancer therapy: The past, present, and future. Pharmacol Rev  2024,76(3),414-453","journal-title":"Pharmacol Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3892\/ijo.2015.3274","volume":"48","author":"Grossebrummel H.","year":"2016","unstructured":"Grossebrummel H.; Peter T.; Mandelkow R.; Weiss M.; Muzzio D.; Zimmermann U.; Walther R.; Jensen F.; Knabbe C.; Zygmunt M.; Burchardt M.; Stope M.B.; Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol  2016,48(2),793-800","journal-title":"Int J Oncol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","volume":"287","author":"Soifer H.S.","year":"2012","unstructured":"Soifer H.S.; Souleimanian N.; Wu S.; Voskresenskiy A.M.; Collak F.K.; Cinar B.; Stein C.A.; Prostate cancer cells activity by potent CYP17 inhibitors in direct regulation of androgen receptor. J Biol Chem  2012,287(6),3777-3787","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-08-0336","volume":"7","author":"Bruno R.D.","year":"2008","unstructured":"Bruno R.D.; Gover T.D.; Burger A.M.; Brodie A.M.; Njar V.C.O.; 17\u03b1-Hydroxylase\/17,20 lyase inhibitor VN\/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol Cancer Ther  2008,7(9),2828-2836","journal-title":"Mol Cancer Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","volume":"7","author":"Vasaitis T.","year":"2008","unstructured":"Vasaitis T.; Belosay A.; Schayowitz A.; Khandelwal A.; Chopra P.; Gediya L.K.; Guo Z.; Fang H.B.; Njar V.C.O.; Brodie A.M.H.; Androgen receptor inactivation contributes to antitumor efficacy of 17\u03b1-hydroxylase\/17,20-lyase inhibitor 3\u03b2-hydroxy-17-(1 H -benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther  2008,7(8),2348-2357","journal-title":"Mol Cancer Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1021\/jm400048v","volume":"56","author":"Purushottamachar P.","year":"2013","unstructured":"Purushottamachar P.; Godbole A.M.; Gediya L.K.; Martin M.S.; Vasaitis T.S.; Kwegyir-Afful A.K.; Ramalingam S.; Ates-Alagoz Z.; Njar V.C.O.; Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem  2013,56(12),4880-4898","journal-title":"J Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1021\/acsmedchemlett.6b00137","volume":"7","author":"Purushottamachar P.","year":"2016","unstructured":"Purushottamachar P.; Kwegyir-Afful A.K.; Martin M.S.; Ramamurthy V.P.; Ramalingam S.; Njar V.C.O.; Identification of novel steroidal androgen receptor degrading agents inspired by galeterone 3\u03b2-imidazole carbamate. ACS Med Chem Lett  2016,7(7),708-713","journal-title":"ACS Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"12460","DOI":"10.1021\/acs.jmedchem.2c01164","volume":"65","author":"Wang A.","year":"2022","unstructured":"Wang A.; Luo X.; Wang Y.; Meng X.; Lu Z.; Yang Y.; Design, synthesis, and biological evaluation of androgen receptor degrading and antagonizing bifunctional steroidal analogs for the treatment of advanced prostate cancer. J Med Chem  2022,65(18),12460-12481","journal-title":"J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"27440","DOI":"10.18632\/oncotarget.4578","volume":"6","author":"Kwegyir-Afful A.K.","year":"2015","unstructured":"Kwegyir-Afful A.K.; Ramalingam S.; Purushottamachar P.; Ramamurthy V.P.; Njar V.C.O.; Galeterone and VNPT55 induce proteasomal degradation of AR\/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget  2015,6(29),27440-27460","journal-title":"Oncotarget"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"24992","DOI":"10.18632\/oncotarget.25167","volume":"9","author":"McClurg U.L.","year":"2018","unstructured":"McClurg U.L.; Azizyan M.; Dransfield D.T.; Namdev N.; Chit N.C.T.H.; Nakjang S.; Robson C.N.; The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival. Oncotarget  2018,9(38),24992-25007","journal-title":"Oncotarget"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"LBA027","DOI":"10.1158\/1535-7163.TARG-21-LBA027","volume":"20","author":"Thomas E.","year":"2021","unstructured":"Thomas E.; Thankan R.S.; Purushottamachar P.; Njar V.C.O.; Abstract LBA027: Mechanistic insights on the effects of the lead next generation galeterone analog, VNPP433-3\u03b2 in castration resistant prostate cancer. Mol Cancer Ther  2021,20(12_supplement),LBA027-7","journal-title":"Mol Cancer Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.3390\/cancers15041198","volume":"15","author":"Thomas E.","year":"2023","unstructured":"Thomas E.; Thankan R.S.; Purushottamachar P.; Weber D.J.; Njar V.C.O.; Targeted degradation of androgen receptor by VNPP433-3\u03b2 in castration-resistant prostate cancer cells implicates interaction with E3 ligase MDM2 resulting in ubiquitin-proteasomal degradation. Cancers  2023,15(4),1198","journal-title":"Cancers"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.3390\/cells11172699","volume":"11","author":"Thomas E.","year":"2022","unstructured":"Thomas E.; Thankan R.S.; Purushottamachar P.; Huang W.; Kane M.A.; Zhang Y.; Ambulos N.P.; Weber D.J.; Njar V.C.O.; Novel AR\/AR-V7 and Mnk1\/2 degrader, VNPP433-3\u03b2: Molecular mechanisms of action and efficacy in AR-overexpressing castration resistant prostate cancer in vitro and in vivo models. Cells  2022,11(17),2699","journal-title":"Cells"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"88501","DOI":"10.18632\/oncotarget.19762","volume":"8","author":"McCarty D.J.","year":"2017","unstructured":"McCarty D.J.; Huang W.; Kane M.A.; Purushottamachar P.; Gediya L.K.; Njar V.C.O.; Novel galeterone analogs act independently of AR and AR-V7 for the activation of the unfolded protein response and induction of apoptosis in the CWR22Rv1 prostate cancer cell model. Oncotarget  2017,8(51),88501-88516","journal-title":"Oncotarget"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/cancers11111637","volume":"11","author":"Kwegyir-Afful A.K.","year":"2019","unstructured":"Kwegyir-Afful A.K.; Ramalingam S.; Ramamurthy V.P.; Purushottamachar P.; Murigi F.N.; Vasaitis T.S.; Huang W.; Kane M.A.; Zhang Y.; Ambulos N.; Tiwari S.; Srivastava P.; Nnane I.P.; Hussain A.; Qiu Y.; Weber D.J.; Njar V.C.O.; Galeterone and the next generation galeterone analogs, VNPP414 and VNPP433-3\u03b2 exert potent therapeutic effects in castration-\/drug-resistant prostate cancer preclinical models in vitro and in vivo. Cancers  2019,11(11),1637","journal-title":"Cancers"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1111\/febs.13895","volume":"283","author":"Kwegyir-Afful A.K.","year":"2016","unstructured":"Kwegyir-Afful A.K.; Bruno R.D.; Purushottamachar P.; Murigi F.N.; Njar V.C.O.; Galeterone and VNPT 55 disrupt Mnk\u2010 eIF 4E to inhibit prostate cancer cell migration and invasion. FEBS J  2016,283(21),3898-3918","journal-title":"FEBS J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00280-020-04195-w","volume":"87","author":"Xu Y.","year":"2021","unstructured":"Xu Y.; Liao S.; Wang L.; Wang Y.; Wei W.; Su K.; Tu Y.; Zhu S.; Galeterone sensitizes breast cancer to chemotherapy via targeting MNK\/eIF4E and \u03b2-catenin. Cancer Chemother Pharmacol  2021,87(1),85-93","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"52381","DOI":"10.18632\/oncotarget.14154","volume":"8","author":"Kwegyir-Afful A.K.","year":"2017","unstructured":"Kwegyir-Afful A.K.; Murigi F.N.; Purushottamachar P.; Ramamurthy V.P.; Martin M.S.; Njar V.C.O.; Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget  2017,8(32),52381-52402","journal-title":"Oncotarget"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/157489207779561453","volume":"2","author":"Baston E.","year":"2007","unstructured":"Baston E.; Leroux F.; Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development. Recent Patents Anticancer Drug Discov  2007,2(1),31-58","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2174\/092986708783955428","volume":"15","author":"Moreira V.","year":"2008","unstructured":"Moreira V.; Salvador J.; Vasaitis T.; Njar V.; CYP17 inhibitors for prostate cancer treatment--an update. Curr Med Chem  2008,15(9),868-899","journal-title":"Curr Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/187152009788680046","volume":"9","author":"Owen C.P.","year":"2009","unstructured":"Owen C.P.; 17\u03b1-hydroxylase\/17,20-lyase (p450(17\u03b1)) inhibitors in the treatment of prostate cancer: A review. Anticancer Agents Med Chem  2009,9(6),613-626","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","volume":"125","author":"Vasaitis T.S.","year":"2011","unstructured":"Vasaitis T.S.; Bruno R.D.; Njar V.C.O.; CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol  2011,125(1-2),23-31","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jsbmb.2013.04.006","volume":"137","author":"Salvador J.A.R.","year":"2013","unstructured":"Salvador J.A.R.; Pinto R.M.A.; Silvestre S.M.; Steroidal 5\u03b1-reductase and 17\u03b1-hydroxylase\/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. J Steroid Biochem Mol Biol  2013,137,199-222","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.5772\/52290","author":"Salvador J.A.R.","year":"2013","unstructured":"Salvador J.A.R.; Moreira V.M.; Silvestre S.M.; Steroidal CYP17 inhibitors for prostate cancer treatment: From concept to clinic. In:  Advances in Prostate Cancer; Hamilton, G, Ed; InTechOpen: London, UK  2013","journal-title":"Advances in Prostate Cancer; Hamilton, G, Ed; InTechOpen: London, UK"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jsbmb.2013.02.018","volume":"137","author":"Frank \u00c9.","year":"2013","unstructured":"Frank \u00c9.; Schneider G.; Synthesis of sex hormone-derived modified steroids possessing antiproliferative activity. J Steroid Biochem Mol Biol  2013,137,301-315","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/0929867323666160210125642","volume":"23","author":"Cabeza M.","year":"2016","unstructured":"Cabeza M.; S\u00e1nchez-M\u00e1rquez A.; Garrido M.; Silva A.; Bratoeff E.; Recent advances in drug design and drug discovery for androgen-dependent diseases. Curr Med Chem  2016,23(8),792-815","journal-title":"Curr Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/pharmaceutics16111401","volume":"16","author":"Kuzminac I.Z.","year":"2024","unstructured":"Kuzminac I.Z.; Nikoli\u0107 A.R.; Savi\u0107 M.P.; Ajdukovi\u0107 J.J.; Abiraterone and galeterone, powerful tools against prostate cancer: Present and perspective. Pharmaceutics  2024,16(11),1401","journal-title":"Pharmaceutics"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"202203393","DOI":"10.1002\/slct.202203393","volume":"7","author":"Zolottsev V.A.","year":"2022","unstructured":"Zolottsev V.A.; Latysheva A.S.; Khan I.I.; Pokrovsky V.S.; Misharin A.Y.; Design and synthesis of new agents for prostate cancer treatment inspired by steroidal CYP17 A1 inhibitors. ChemistrySelect  2022,7(45),202203393","journal-title":"ChemistrySelect"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2100316","DOI":"10.1002\/ardp.202100316","volume":"355","author":"Khan I.I.","year":"2022","unstructured":"Khan I.I.; Karshieva S.S.; Sokolova D.V.; Spirina T.S.; Zolottsev V.A.; Latysheva A.S.; Anisimova N.Y.; Komarova M.V.; Yakunina M.N.; Nitetskaya T.A.; Misharin A.Y.; Pokrovsky V.S.; Antiproliferative, proapoptotic, and tumor\u2010suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts. Arch Pharm  2022,355(1),2100316","journal-title":"Arch Pharm"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"106280","DOI":"10.1016\/j.jsbmb.2023.106280","volume":"230","author":"Latysheva A.S.","year":"2023","unstructured":"Latysheva A.S.; Zolottsev V.A.; Veselovsky A.V.; Scherbakov K.A.; Morozevich G.E.; Zhdanov D.D.; Novikov R.A.; Misharin A.Y.; Oxazolinyl derivatives of androst-16-ene as inhibitors of CYP17A1 activity and prostate carcinoma cells proliferation: Effects of substituents in oxazolinyl moiety. J Steroid Biochem Mol Biol  2023,230,106280","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1016\/j.bmc.2015.10.015","volume":"23","author":"Jakimov D.S.","year":"2015","unstructured":"Jakimov D.S.; Koji\u0107 V.V.; Aleksi\u0107 L.D.; Bogdanovi\u0107 G.M.; Ajdukovi\u0107 J.J.; Djurendi\u0107 E.A.; Penov Ga\u0161i K.M.; Saka\u010d M.N.; Jovanovi\u0107-\u0160anta S.S.; Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells. Bioorg Med Chem  2015,23(22),7189-7198","journal-title":"Bioorg Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejmech.2017.12.094","volume":"145","author":"Shi Y.K.","year":"2018","unstructured":"Shi Y.K.; Wang B.; Shi X.L.; Zhao Y.D.; Yu B.; Liu H.M.; Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents. Eur J Med Chem  2018,145,11-22","journal-title":"Eur J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"103142","DOI":"10.1016\/j.bioorg.2019.103142","volume":"91","author":"Komendantova A.S.","year":"2019","unstructured":"Komendantova A.S.; Scherbakov A.M.; Komkov A.V.; Chertkova V.V.; Gudovanniy A.O.; Chernoburova E.I.; Sorokin D.V.; Dzichenka Y.U.; Shirinian V.Z.; Volkova Y.A.; Zavarzin I.V.; Novel steroidal 1,3,4-thiadiazines: Synthesis and biological evaluation in androgen receptor-positive prostate cancer 22Rv1 cells. Bioorg Chem  2019,91,103142","journal-title":"Bioorg Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"108465","DOI":"10.1016\/j.steroids.2019.108465","volume":"151","author":"Yang Y.T.","year":"2019","unstructured":"Yang Y.T.; Du S.; Wang S.; Jia X.; Wang X.; Zhang X.; Synthesis of new steroidal quinolines with antitumor properties. Steroids  2019,151,108465","journal-title":"Steroids"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ejmech.2014.06.056","volume":"97","author":"Yu B.","year":"2015","unstructured":"Yu B.; Yu D.Q.; Liu H.M.; Spirooxindoles: Promising scaffolds for anticancer agents. Eur J Med Chem  2015,97,673-698","journal-title":"Eur J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"31607","DOI":"10.1038\/srep31607","volume":"6","author":"Shi X.J.","year":"2016","unstructured":"Shi X.J.; Yu B.; Wang J.W.; Qi P.P.; Tang K.; Huang X.; Liu H.M.; Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanisms. Sci Rep  2016,6(1),31607","journal-title":"Sci Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.steroids.2015.08.003","volume":"102","author":"Yu B.","year":"2015","unstructured":"Yu B.; Sun X.N.; Shi X.J.; Qi P.P.; Zheng Y.C.; Yu D.Q.; Liu H.M.; Efficient synthesis of novel antiproliferative steroidal spirooxindoles via the [3+2] cycloaddition reactions of azomethine ylides. Steroids  2015,102,92-100","journal-title":"Steroids"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jsbmb.2014.01.015","volume":"141","author":"Yu B.","year":"2014","unstructured":"Yu B.; Shi X.J.; Qi P.P.; Yu D.Q.; Liu H.M.; Design, synthesis and biological evaluation of novel steroidal spiro-oxindoles as potent antiproliferative agents. J Steroid Biochem Mol Biol  2014,141,121-134","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbrc.2010.08.121","volume":"400","author":"Amaral J.D.","year":"2010","unstructured":"Amaral J.D.; Castro R.E.; Sol\u00e1 S.; Steer C.J.; Rodrigues C.M.P.; Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53. Biochem Biophys Res Commun  2010,400(4),649-654","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"16906","DOI":"10.1073\/pnas.1215060109","volume":"109","author":"Vogel S.M.","year":"2012","unstructured":"Vogel S.M.; Bauer M.R.; Joerger A.C.; Wilcken R.; Brandt T.; Veprintsev D.B.; Rutherford T.J.; Fersht A.R.; Boeckler F.M.; Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2. Proc Natl Acad Sci USA  2012,109(42),16906-16910","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.3390\/molecules26185675","volume":"26","author":"Ren Y.","year":"2021","unstructured":"Ren Y.; Wu S.; Chen S.; Burdette J.E.; Cheng X.; Kinghorn A.D.; Interaction of (+)-strebloside and its derivatives with Na+\/K+-ATPase and other targets. Molecules  2021,26(18),5675","journal-title":"Molecules"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"109393","DOI":"10.1016\/j.steroids.2024.109393","volume":"205","author":"Xiao Y.","year":"2024","unstructured":"Xiao Y.; Xu B.; Li X.; Ding T.; Zhao W.; Nie X.; Mu J.; Xiao Z.; Wang Q.; Ren Q.; Zhang E.; Potential targets of diosgenin for the treatment of oral squamous cell carcinoma and their bioinformatics and transcriptional profiling analyses. Steroids  2024,205,109393","journal-title":"Steroids"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"106038","DOI":"10.1016\/j.jsbmb.2021.106038","volume":"216","author":"Wang W.","year":"2022","unstructured":"Wang W.; Li C.; Chen Z.; Zhang J.; Ma L.; Tian Y.; Ma Y.; Guo L.; Wang X.; Ye J.; Wang X.; Novel diosgenin-amino acid-benzoic acid mustard trihybrids exert antitumor effects via cell cycle arrest and apoptosis. J Steroid Biochem Mol Biol  2022,216,106038","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1021\/acs.jafc.0c00107","volume":"68","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Zhan Y.; Xu J.; Wang Y.; Sun M.; Chen J.; Liang T.; Wu L.; Xu K.; \u03b2-Sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53\u2212MDM2 interaction in colorectal cancer. J Agric Food Chem  2020,68(12),3850-3858","journal-title":"J Agric Food Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2014.04.009","volume":"350","author":"Dolfi S.C.","year":"2014","unstructured":"Dolfi S.C.; J\u00e4ger A.V.; Medina D.J.; Haffty B.G.; Yang J.M.; Hirshfield K.M.; Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Lett  2014,350(1-2),52-60","journal-title":"Cancer Lett"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"26370","DOI":"10.18632\/oncotarget.25316","volume":"9","author":"Kim G.J.","year":"2018","unstructured":"Kim G.J.; Jo H.J.; Lee K.J.; Choi J.W.; An J.H.; Oleanolic acid induces p53-dependent apoptosis via the ERK\/JNK\/AKT pathway in cancer cell lines in prostatic cancer xenografts in mice. Oncotarget  2018,9(41),26370-26386","journal-title":"Oncotarget"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.1007\/s13277-015-4655-9","volume":"37","author":"Li X.","year":"2016","unstructured":"Li X.; Song Y.; Zhang P.; Zhu H.; Chen L.; Xiao Y.; Xing Y.; Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K\/Akt pathway. Tumour Biol  2016,37(6),7599-7613","journal-title":"Tumour Biol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00432-007-0193-1","volume":"133","author":"Kassi E.","year":"2007","unstructured":"Kassi E.; Papoutsi Z.; Pratsinis H.; Aligiannis N.; Manoussakis M.; Moutsatsou P.; Ursolic acid, a naturally occurring triterpenoid, demonstrates anticancer activity on human prostate cancer cells. J Cancer Res Clin Oncol  2007,133(7),493-500","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1142\/S0192415X15500834","volume":"43","author":"Meng Y.","year":"2015","unstructured":"Meng Y.; Lin Z.M.; Ge N.; Zhang D.L.; Huang J.; Kong F.; Ursolic acid induces apoptosis of prostate cancer cells via the PI3K\/Akt\/mTOR pathway. Am J Chin Med  2015,43(7),1471-1486","journal-title":"Am J Chin Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/molecules22020264","volume":"22","author":"Shankar E.","year":"2017","unstructured":"Shankar E.; Zhang A.; Franco D.; Gupta S.; Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa B (NF-\u03baB) pathways. Molecules  2017,22(2),264","journal-title":"Molecules"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-06-3735","volume":"67","author":"Chintharlapalli S.","year":"2007","unstructured":"Chintharlapalli S.; Papineni S.; Ramaiah S.K.; Safe S.; Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res  2007,67(6),2816-2823","journal-title":"Cancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"56234","DOI":"10.1371\/journal.pone.0056234","volume":"8","author":"Reiner T.","year":"2013","unstructured":"Reiner T.; Parrondo R.; de las Pozas A.; Palenzuela D.; Perez-Stable C.; Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: Possible role for inhibition of deubiquitinase activity. PLoS One  2013,8(2),56234","journal-title":"PLoS One"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"13146","DOI":"10.1038\/s41598-018-31567-3","volume":"8","author":"de las Pozas A.","year":"2018","unstructured":"de las Pozas A.; Reiner T.; De Cesare V.; Trost M.; Perez-Stable C.; Inhibiting multiple deubiquitinases to reduce androgen receptor expression in prostate cancer cells. Sci Rep  2018,8(1),13146","journal-title":"Sci Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3892\/ijo.2011.1061","volume":"39","author":"Gnanasekar M.","year":"2011","unstructured":"Gnanasekar M.; Thirugnanam S.; Dakshinamoorthy G.; Samykutty A.; Zheng G.; Chen A.; Bosland M.C.; Kajdacsy-Balla A.; Gnanasekar M.; 18\u03b1-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. Int J Oncol  2011,39(3),635-640","journal-title":"Int J Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1134\/S0026893317050090","volume":"51","author":"Frolova T.S.","year":"2017","unstructured":"Frolova T.S.; Lipeeva A.V.; Baev D.S.; Tsepilov Y.A.; Sinitsyna O.I.; Apoptosis as the basic mechanism of cytotoxic action of ursolic and pomolic acids in glioma cells. Mol Biol  2017,51(5),705-711","journal-title":"Mol Biol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/molecules25010155","volume":"25","author":"Muhseen Z.T.","year":"2019","unstructured":"Muhseen Z.T.; Li G.; Promising terpenes as natural antagonists of cancer: An in-silico approach. Molecules  2019,25(1),155","journal-title":"Molecules"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/13543776.2014.927441","volume":"24","author":"Csuk R.","year":"2014","unstructured":"Csuk R.; Betulinic acid and its derivatives: A patent review (2008-2013). Expert Opin Ther Pat  2014,24(8),913-923","journal-title":"Expert Opin Ther Pat"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.3390\/molecules26164957","volume":"26","author":"Baer-Dubowska W.","year":"2021","unstructured":"Baer-Dubowska W.; Naro\u017cna M.; Krajka-Ku\u017aniak V.; Anti-cancer potential of synthetic oleanolic acid derivatives and their conjugates with NSAIDs. Molecules  2021,26(16),4957","journal-title":"Molecules"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"12923","DOI":"10.3390\/ijms241612923","volume":"24","author":"Nistor M.","year":"2023","unstructured":"Nistor M.; Rugina D.; Diaconeasa Z.; Socaciu C.; Socaciu M.A.; Pentacyclic triterpenoid phytochemicals with anticancer activity: Updated studies on mechanisms and targeted delivery. Int J Mol Sci  2023,24(16),12923","journal-title":"Int J Mol Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.biopha.2017.10.027","volume":"96","author":"Abdelmageed N.","year":"2017","unstructured":"Abdelmageed N.; Morad S.A.F.; Elghoneimy A.A.; Syrovets T.; Simmet T.; El-zorba H.; El-Banna H.A.; Cabot M.; Abdel-Aziz M.I.; Oleanolic acid methyl ester, a novel cytotoxic mitocan, induces cell cycle arrest and ROS-Mediated cell death in castration-resistant prostate cancer PC-3 cells. Biomed Pharmacother  2017,96,417-425","journal-title":"Biomed Pharmacother"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.bmcl.2013.01.129","volume":"23","author":"Hao J.","year":"2013","unstructured":"Hao J.; Liu J.; Wen X.; Sun H.; Synthesis and cytotoxicity evaluation of oleanolic acid derivatives. Bioorg Med Chem Lett  2013,23(7),2074-2077","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/14786419.2018.1499642","volume":"34","author":"Xu J.","year":"2020","unstructured":"Xu J.; Wang X.; Zhang H.; Yue J.; Sun Y.; Zhang X.; Zhao Y.; Synthesis of triterpenoid derivatives and their anti-tumor and anti-hepatic fibrosis activities. Nat Prod Res  2020,34(6),766-772","journal-title":"Nat Prod Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/S0960-894X(98)00479-X","volume":"8","author":"Honda T.","year":"1998","unstructured":"Honda T.; Rounds B.V.; Gribble G.W.; Suh N.; Wang Y.; Sporn M.B.; Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett  1998,8,2711-2714","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2014.01.016","volume":"346","author":"Shanmugam M.K.","year":"2014","unstructured":"Shanmugam M.K.; Dai X.; Kumar A.P.; Tan B.K.H.; Sethi G.; Bishayee A.; Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence. Cancer Lett  2014,346(2),206-216","journal-title":"Cancer Lett"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.3390\/molecules24224097","volume":"24","author":"Borella R.","year":"2019","unstructured":"Borella R.; Forti L.; Gibellini L.; De Gaetano A.; De Biasi S.; Nasi M.; Cossarizza A.; Pinti M.; Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids. Molecules  2019,24(22),4097","journal-title":"Molecules"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1124\/mol.107.041285","volume":"73","author":"Papineni S.","year":"2008","unstructured":"Papineni S.; Chintharlapalli S.; Safe S.; Methyl 2-cyano-3,11-dioxo-18 \u03b2-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-\u03b3 agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells. Mol Pharmacol  2008,73(2),553-565","journal-title":"Mol Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/0008-5472.CAN-07-5759","volume":"68","author":"Hyer M.L.","year":"2008","unstructured":"Hyer M.L.; Shi R.; Krajewska M.; Meyer C.; Lebedeva I.V.; Fisher P.B.; Reed J.C.; Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res  2008,68(8),2927-2933","journal-title":"Cancer Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"105034","DOI":"10.1016\/j.compbiomed.2021.105034","volume":"141","author":"Markov A.V.","year":"2022","unstructured":"Markov A.V.; Odarenko K.V.; Ilyina A.A.; Zenkova M.A.; Uncovering the anti-angiogenic effect of semisynthetic triterpenoid CDDO-Im on HUVECs by an integrated network pharmacology approach. Comput Biol Med  2022,141,105034","journal-title":"Comput Biol Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/pros.20937","volume":"69","author":"Deeb D.","year":"2009","unstructured":"Deeb D.; Gao X.; Jiang H.; Dulchavsky S.A.; Gautam S.C.; Oleanane Triterpenoid CDDO\u2010Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro\u2010survival Akt and mTOR. Prostate  2009,69(8),851-860","journal-title":"Prostate"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.bcp.2009.09.006","volume":"79","author":"Deeb D.","year":"2010","unstructured":"Deeb D.; Gao X.; Jiang H.; Janic B.; Arbab A.S.; Rojanasakul Y.; Dulchavsky S.A.; Gautam S.C.; Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol  2010,79(3),350-360","journal-title":"Biochem Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.bbrc.2011.12.007","volume":"417","author":"Liu Y.","year":"2012","unstructured":"Liu Y.; Gao X.; Deeb D.; Gautam S.C.; Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells. Biochem Biophys Res Commun  2012,417(1),570-575","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ejmech.2015.03.048","volume":"95","author":"Cui H.W.","year":"2015","unstructured":"Cui H.W.; He Y.; Wang J.; Gao W.; Liu T.; Qin M.; Wang X.; Gao C.; Wang Y.; Liu M.Y.; Yi Z.; Qiu W.W.; Synthesis of heterocycle-modified betulinic acid derivatives as antitumor agents. Eur J Med Chem  2015,95,240-248","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1016\/j.bmc.2006.05.048","volume":"14","author":"Saxena B.","year":"2006","unstructured":"Saxena B.; Zhu L.; Hao M.; Kisilis E.; Katdare M.; Oktem O.; Bomshteyn A.; Rathnam P.; Boc-lysinated-betulonic acid: A potent, anti-prostate cancer agent. Bioorg Med Chem  2006,14(18),6349-6358","journal-title":"Bioorg Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1016\/j.bmc.2017.08.002","volume":"25","author":"Li K.","year":"2017","unstructured":"Li K.; Ma T.; Cai J.; Huang M.; Guo H.; Zhou D.; Luan S.; Yang J.; Liu D.; Jing Y.; Zhao L.; Conjugates of 18\u03b2-glycyrrhetinic acid derivatives with 3-(1H-benzo[d]imidazol-2-yl)propanoic acid as Pin1 inhibitors displaying anti-prostate cancer ability. Bioorg Med Chem  2017,25(20),5441-5451","journal-title":"Bioorg Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"108698","DOI":"10.1016\/j.steroids.2020.108698","volume":"162","author":"Popov S.A.","year":"2020","unstructured":"Popov S.A.; Semenova M.D.; Baev D.S.; Frolova T.S.; Shestopalov M.A.; Wang C.; Qi Z.; Shults E.E.; Turks M.; Synthesis and cytotoxicity of hybrids of 1,3,4- or 1,2,5-oxadiazoles tethered from ursane and lupane core with 1,2,3-triazole. Steroids  2020,162,108698","journal-title":"Steroids"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.intimp.2007.01.008","volume":"7","author":"Moradali M.F.","year":"2007","unstructured":"Moradali M.F.; Mostafavi H.; Ghods S.; Hedjaroude G.A.; Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol  2007,7(6),701-724","journal-title":"Int Immunopharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.bmcl.2009.02.119","volume":"19","author":"Liu J.","year":"2009","unstructured":"Liu J.; Shiono J.; Shimizu K.; Kukita A.; Kukita T.; Kondo R.; Ganoderic acid DM: Anti-androgenic osteoclastogenesis inhibitor. Bioorg Med Chem Lett  2009,19(8),2154-2157","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3892\/ijmm.21.5.577","volume":"21","author":"Jiang J.","year":"2008","unstructured":"Jiang J.; Grieb B.; Thyagarajan A.; Sliva D.; Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-\u03baB signaling. Int J Mol Med  2008,21(5),577-584","journal-title":"Int J Mol Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.lfs.2004.09.045","volume":"77","author":"Li C.H.","year":"2005","unstructured":"Li C.H.; Chen P.Y.; Chang U.M.; Kan L.S.; Fang W.H.; Tsai K.S.; Lin S.B.; Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells. Life Sci  2005,77(3),252-265","journal-title":"Life Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lfs.2006.09.001","volume":"80","author":"Tang W.","year":"2006","unstructured":"Tang W.; Liu J.W.; Zhao W.M.; Wei D.Z.; Zhong J.J.; Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci  2006,80(3),205-211","journal-title":"Life Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.3892\/mmr.2017.7048","volume":"16","author":"Wang X.","year":"2017","unstructured":"Wang X.; Sun D.; Tai J.; Wang L.; Ganoderic acid A inhibits proliferation and invasion, and promotes apoptosis in human hepatocellular carcinoma cells. Mol Med Rep  2017,16(4),3894-3900","journal-title":"Mol Med Rep"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"22392","DOI":"10.1002\/jbt.22392","volume":"33","author":"Cheng Y.","year":"2019","unstructured":"Cheng Y.; Xie P.; Ganoderic acid A holds promising cytotoxicity on human glioblastoma mediated by incurring apoptosis and autophagy and inactivating PI3K\/AKT signaling pathway. J Biochem Mol Toxicol  2019,33(11),22392","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1002\/jcb.27913","volume":"120","author":"Johnson B.M.","year":"2019","unstructured":"Johnson B.M.; Radwan F.F.Y.; Hossain A.; Doonan B.P.; Hathaway-Schrader J.D.; God J.M.; Voelkel-Johnson C.V.; Banik N.L.; Reddy S.V.; Haque A.; Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells. J Cell Biochem  2019,120(4),6264-6276","journal-title":"J Cell Biochem"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/molecules28052374","volume":"28","author":"Jia Y.","year":"2023","unstructured":"Jia Y.; Li Y.; Shang H.; Luo Y.; Tian Y.; Ganoderic acid A and its amide derivatives as potential anti-cancer agents by regulating the p53-MDM2 pathway: Synthesis and biological evaluation. Molecules  2023,28(5),2374","journal-title":"Molecules"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/14756366.2012.658787","volume":"28","author":"Froufe H.J.C.","year":"2013","unstructured":"Froufe H.J.C.; Abreu R.M.V.; Ferreira I.C.F.R.; Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors. J Enzyme Inhib Med Chem  2013,28(3),569-575","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"4668","DOI":"10.2174\/138161212802651580","volume":"18","author":"Khoury K.","year":"2012","unstructured":"Khoury K.; Domling A.; P53-MDM2 inhibitors. Curr Pharm Des  2012,18,4668-4678","journal-title":"Curr Pharm Des"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00044-020-02574-9","volume":"29","author":"Anifowose A.","year":"2020","unstructured":"Anifowose A.; Agbowuro A.A.; Yang X.; Wang B.; Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2. Med Chem Res  2020,29(7),1105-1121","journal-title":"Med Chem Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/molecules25051211","volume":"25","author":"Beloglazkina A.","year":"2020","unstructured":"Beloglazkina A.; Zyk N.; Majouga A.; Beloglazkina E.; Recent small-molecule inhibitors of the p53-MDM2 protein-protein interaction. Molecules  2020,25(5),1211","journal-title":"Molecules"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5582\/ddt.2015.01004","volume":"9","author":"Ru W.","year":"2015","unstructured":"Ru W.; Wang D.; Xu Y.; He X.; Sun Y.E.; Qian L.; Zhou X.; Qin Y.; Chemical constituents and bioactivities of Panax ginseng (C. A. Mey.). Drug Discov Ther  2015,9(1),23-32","journal-title":"Drug Discov Ther"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1517\/13543776.2015.1038239","volume":"25","author":"Cao J.","year":"2015","unstructured":"Cao J.; Zhang X.; Qu F.; Guo Z.; Zhao Y.; Dammarane triterpenoids for pharmaceutical use: A patent review (2005-2014). Expert Opin Ther Pat  2015,25(7),805-817","journal-title":"Expert Opin Ther Pat"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1142\/S0192415X17500628","volume":"45","author":"Park J.","year":"2017","unstructured":"Park J.; Bui P.T.C.; Song H.; Kim S.K.; Rhee D.K.; Kim E.Y.; Rhyu M.R.; Lee M.S.; Lee Y.J.; Ginseng on nuclear hormone receptors. Am J Chin Med  2017,45(6),1147-1156","journal-title":"Am J Chin Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.2174\/1568026619666191018100848","volume":"19","author":"Guo Y.","year":"2019","unstructured":"Guo Y.; Kuruganti R.; Gao Y.; Recent Advances in ginsenosides as potential therapeutics against breast cancer. Curr Top Med Chem  2019,19(25),2334-2347","journal-title":"Curr Top Med Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1142\/S0192415X19500885","volume":"47","author":"Xiao H.","year":"2019","unstructured":"Xiao H.; Xue Q.; Zhang Q.; Li C.; Liu X.; Liu J.; Li H.; Yang J.; How ginsenosides trigger apoptosis in human lung adenocarcinoma cells. Am J Chin Med  2019,47(8),1737-1754","journal-title":"Am J Chin Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1875-5364(20)30063-7","volume":"18","author":"Tian M.","year":"2020","unstructured":"Tian M.; Li L.N.; Zheng R.R.; Yang L.; Wang Z.T.; Advances on hormone-like activity of Panax ginseng and ginsenosides. Chin J Nat Med  2020,18(7),526-535","journal-title":"Chin J Nat Med"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4172\/2161-0444.1000437","volume":"7","author":"Wu S.","year":"2017","unstructured":"Wu S.; Ding M.; Wang X.; Li W.; Zhao Y.; 25-Methoxyl-dammarane-3\u03b2, 12\u03b2, 20-triol, a ginseng saponin derivative and an anticancer agent: in vitro and in vivo activities, molecular mechanism of action, pharmacokinetics and structural modification. Med Chem  2017,7(3),832-836","journal-title":"Med Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.canlet.2009.01.005","volume":"278","author":"Wang W.","year":"2009","unstructured":"Wang W.; Rayburn E.R.; Zhao Y.; Wang H.; Zhang R.; Novel ginsenosides 25-OH-PPD and 25-OCH3 -PPD as experimental therapy for pancreatic cancer: Anticancer activity and mechanisms of action. Cancer Lett  2009,278(2),241-248","journal-title":"Cancer Lett"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/157340607779317508","volume":"3","author":"Zhao Y.","year":"2007","unstructured":"Zhao Y.; Wang W.; Han L.; Rayburn E.; Hil D.; Wang H.; Zhang R.; Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3\u03b2, 12\u03b2, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med Chem  2007,3(1),51-60","journal-title":"Med Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/sj.bjc.6604227","volume":"98","author":"Wang W.","year":"2008","unstructured":"Wang W.; Wang H.; Rayburn E.R.; Zhao Y.; Hill D.L.; Zhang R.; 20(S)-25-methoxyl-dammarane-3\u03b2, 12\u03b2, 20-triol, a novel natural product for prostate cancer therapy: Activity in vitro and in vivo and mechanisms of action. Br J Cancer  2008,98(4),792-802","journal-title":"Br J Cancer"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/ijc.27754","volume":"132","author":"Cao B.","year":"2013","unstructured":"Cao B.; Liu X.; Li J.; Liu S.; Qi Y.; Xiong Z.; Zhang A.; Wiese T.; Fu X.; Gu J.; Rennie P.S.; Sartor O.; Lee B.R.; Ip C.; Zhao L.; Zhang H.; Dong Y.; 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer  2013,132(6),1277-1287","journal-title":"Int J Cancer"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fphar.2020.00521","volume":"11","author":"Kim D.","year":"2020","unstructured":"Kim D.; Park M.; Haleem I.; Lee Y.; Koo J.; Na Y.C.; Song G.; Lee J.; Natural product ginsenoside 20(S)-25-methoxyl-dammarane-3\u03b2, 12\u03b2, 20-triol in cancer treatment: A review of the pharmacological mechanisms and pharmacokinetics. Front Pharmacol  2020,11,521","journal-title":"Front Pharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/carcin\/bgy063","volume":"39","author":"Wang W.","year":"2018","unstructured":"Wang W.; Qin J.J.; Li X.; Tao G.; Wang Q.; Wu X.; Zhou J.; Zi X.; Zhang R.; Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis  2018,39(8),1026-1036","journal-title":"Carcinogenesis"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.steroids.2013.09.010","volume":"78","author":"Liu Y.F.","year":"2013","unstructured":"Liu Y.F.; Yuan H.N.; Bi X.L.; Piao H.R.; Cao J.Q.; Li W.; Wang P.; Zhao Y.Q.; 25-Methoxylprotopanaxadiol derivatives and their anti-proliferative activities. Steroids  2013,78(14),1305-1311","journal-title":"Steroids"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejphar.2016.12.027","volume":"798","author":"Wang X.D.","year":"2017","unstructured":"Wang X.D.; Sun Y.Y.; Zhao C.; Qu F.Z.; Zhao Y.Q.; 12-Chloracetyl-PPD, a novel dammarane derivative, shows anti-cancer activity via delay the progression of cell cycle G2\/M phase and reactive oxygen species-mediate cell apoptosis. Eur J Pharmacol  2017,798,49-56","journal-title":"Eur J Pharmacol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.steroids.2012.09.012","volume":"78","author":"Wang P.","year":"2013","unstructured":"Wang P.; Bi X.L.; Xu J.; Yuan H.N.; Piao H.R.; Zhao Y.Q.; Synthesis and anti-tumor evaluation of novel 25-hydroxyprotopanaxadiol analogs incorporating natural amino acids. Steroids  2013,78(2),203-209","journal-title":"Steroids"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jgr.2016.12.014","volume":"42","author":"Wang X.D.","year":"2018","unstructured":"Wang X.D.; Su G.Y.; Zhao C.; Qu F.Z.; Wang P.; Zhao Y.Q.; Anticancer activity and potential mechanisms of 1C, a ginseng saponin derivative, on prostate cancer cells. J Ginseng Res  2018,42(2),133-143","journal-title":"J Ginseng Res"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.3390\/molecules28217400","volume":"28","author":"Lin L.","year":"2023","unstructured":"Lin L.; Zhao Y.; Wang P.; Li T.; Liang Y.; Chen Y.; Meng X.; Zhang Y.; Su G.; Amino acid derivatives of ginsenoside AD-2 induce HepG2 cell apoptosis by affecting the cytoskeleton. Molecules  2023,28(21),7400","journal-title":"Molecules"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"111964","DOI":"10.1016\/j.ejmech.2019.111964","volume":"187","author":"Ma L.","year":"2020","unstructured":"Ma L.; Wang X.; Li W.; Miao D.; Li Y.; Lu J.; Zhao Y.; Synthesis and anti-cancer activity studies of dammarane-type triterpenoid derivatives. Eur J Med Chem  2020,187,111964","journal-title":"Eur J Med Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673373971250625075309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244211\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673373971250625075309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:51:00Z","timestamp":1791877860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244211\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":134,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673373971250625075309","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}